New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

The stock market, as measured by the S&P 500 index of 500 of America's biggest companies, is down 5.4% so far this year, as of March 24. When the S&P 500 is down, it means that more than a few companies' stocks are also down. And with dividend-paying stocks, a lower stock price means a boosted dividend yield. So, which dividend payer might you consider for your long-term portfolio, whether you have $10,000 or $100 or $100,000 to invest? Well, I suggest buying a bunch of solid dividend payers via a single ex ...

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

NYMOX Provides Recent Updates <!-- Twitter Tags --> <!-- Facebook Tags --> <!-- Injecting site-wide to the head --> <!-- End Injecting site-wide to the head --><!-- Inject secured cdn script --> <!-- ========= Meta Tags ========= --> <!-- PWA settings --> <!-- Add manifest --> <!-- End PWA settings --> <!--Add favorites icons--><!-- End favorite icons --> <!-- render the required CSS and JS in the head section --> <!-- loadCSS function header.jsp--> <!-- Google Fonts Include --><!-- loadCSS function fonts.j ...

Key Takeaways Novartis to acquire Excellergy for up to $2B, adding Exl-111 to expand its IgE-focused pipeline.NVS strengthens allergy franchise with next-gen anti-IgE therapy targeting food allergy and asthma.Deal aligns with immunology push as Novartis advances pipeline amid patent and generic pressures.Novartis (NVS) has announced the proposed acquisition of Excellergy Inc., reinforcing its strategic focus on expanding its immunology pipeline, particularly in food allergy and other IgE-mediated diseases.E ...

As filed with the U.S. Securities and Exchange Commission on March 27, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Cayman Islands | 5122 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification No.) | Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong +852 2618-9289 ( ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”).Investor ...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

The Dow Jones Industrial Average (^DJI) was down 710.40 (-1.55%) points today, falling to 45,249.71. Similarly, Dow Futures (YM=F) was down 685.00 (-1.48%) points at 45,545.00. The primary narrative driving this sharp decline was the release of the February Personal Consumption Expenditures (PCE) price index, which revealed that inflationary pressures remain more persistent than economists had anticipated. This data, combined with hawkish policy signals from Federal Reserve officials, led traders to price o ...